SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001437749-23-027767
Filing Date
2023-10-05
Accepted
2023-10-05 16:21:49
Documents
3
Period of Report
2023-11-16

Document Format Files

Seq Description Document Type Size
1 FORM DEF 14A navb20231003_def14a.htm DEF 14A 747030
2 navb20231003_def14aimg001.jpg GRAPHIC 26365
3 navb20231003_def14aimg002.jpg GRAPHIC 25154
  Complete submission text file 0001437749-23-027767.txt   819391
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-35076 | Film No.: 231311628
SIC: 2835 In Vitro & In Vivo Diagnostic Substances